RhoB enhances migration and MMP1 expression of prostate cancer DU145

Experimental and Molecular Pathology

Volumn 88, Issue 1, 2010, Pages 90-95

  Yoneda, Misao ^a   Hirokawa, Yoshifumi S ^b   Ohashi, Atsuyuki ^b   Uchida, Katsunori ^b   Kami, Daisuke ^c   Watanabe, Masatoshi ^c   Yokoi, Toyoharu ^a   Shiraishi, Taizo ^b   Wakusawa, Shinya ^a  

^a NAGOYA UNIVERSITY   (Japan)

^b Faculty of Medicine   (Japan)

^c Graduate School of Engineering   (Japan)

Author keywords

GSK 3; MMP1; Prostate cancer; RhoB

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; INDIRUBIN 3' MONOXIME 5 SULFONIC ACID; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE INHIBITOR; RHOB GUANINE NUCLEOTIDE BINDING PROTEIN; RNA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; MALE; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MALE; MATRIX METALLOPROTEINASE 1; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; RHOB GTP-BINDING PROTEIN; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 74749087388     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2009.09.010     Document Type: Article

References (28)

1. Adamson P., Paterson H.F., and Hall A. Intracellular localization of the P21rho proteins. J. Cell Biol. 119 (1992) 617-627
2. Allal C., Pradines A., Hamilton A.D., Sebti S.M., and Favre G. Farnesylated RhoB prevents cell cycle arrest and actin cytoskeleton disruption caused by the geranylgeranyltransferase I inhibitor GGTI-298. Cell Cycle 1 (2002) 430-437
3. Brown M.C., and Turner C.E. Paxillin adapting to change. Physiol. Rev. 84 (2004) 1315-1339
4. Cai X., Li M., Vrana J., and Schaller M.D. Glycogen synthase kinase 3- and extracellular signal-regulated kinase-dependent phosphorylation of paxillin regulates cytoskeletal rearrangement. Mol. Cell Biol. 26 (2006) 2857-2868
5. Chen Z., Sun J., Pradines A., Favre G., Adnane J., and Sebti S.M. Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice. J. Biol. Chem. 275 (2000) 17974-17978
6. Doble B.W., and Woodgett J.R. GSK-3: tricks of the trade for a multi-tasking kinase. J. Cell Sci. 116 Part 7 (2003) 1175-1186
7. Farooqui R., Zhu S., and Fenteany G. Glycogen synthase kinase-3 acts upstream of ADP-ribosylation factor 6 and Rac1 to regulate epithelial cell migration. Exp. Cell Res. 312 (2006) 1514-1525
8. Jiang K., Sun J., Cheng J., Djeu J.Y., Wei S., and Sebti S. Akt mediates Ras downregulation of RhoB, a suppressor of transformation, invasion, and metastasis. Mol. Cell. Biol. 24 (2004) 5565-5576
9. Kozma R., Ahmed S., Best A., and Lim L. The Ras-related protein Cdc42Hs and bradykinin promote formation of peripheral actin microspikes and filopodia in Swiss 3T3 fibroblasts. Mol. Cell. Biol. 15 (1995) 1942-1952
10. Kulkarni N.H., Wei T., Kumar A., Dow E.R., Stewart T.R., Shou J., N'cho M., Sterchi D.L., Gitter B.D., Higgs R.E., Halladay D.L., Engler T.A., Martin T.J., Bryant H.U., Ma Y.L., and Onyia J.E. Changes in osteoblast, chondrocyte, and adipocyte lineages mediate the bone anabolic actions of PTH and small molecule GSK-3 inhibitor. J. Cell Biochem. 102 (2007) 1504-1518
11. Li Y., Bharti A., Chen D., Gong J., and Kufe D. Interaction of glycogen synthase kinase 3beta with the DF3/MUC1 carcinoma-associated antigen and beta-catenin. Mol. Cell. Biol. 18 (1998) 7216-7224
12. Liu A., Du W., Liu J.P., Jessell T.M., and Prendergast G.C. RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors. Mol. Cell. Biol. 20 (2000) 6105-6113
13. Liu A.X., Rane N., Liu J.P., and Prendergast G.C. RhoB is dispensable for mouse development but it modifies susceptibility to tumor formation as well as cell adhesion and growth factor signaling in transformed cells. Mol. Cell. Biol. 20 (2001) 6906-6912
14. Moasser M.M., Sepp-Lorenzino L., Kohl N.E., Oliff A., Balog A., Su D.S., Danishefsky S.J., and Rosen N. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 1369-1374
15. Murray G.I., Duncan M.E., O'Neil P., Melvin W.T., and Fothergill J.E. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat. Med. 2 (1996) 461-462
16. Prendergast G.C. Actin' up RhoB in cancer and apoptosis. Nat. Rev. Cancer 1 (2001) 162-168
17. Ridley A.J., and Hall A. The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 70 (1992) 389-399
18. Ridley A.J., Paterson H.F., Johnston C.L., Diekmann D., and Hall A. The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell 70 (1992) 401-410
19. Sandilands E., Cans C., Fincham V.J., Brunton V.G., Mellor H., Prendergast G.C., Norman J.C., Superti-Furga G., and Frame M.C. RhoB and actin polymerization coordinate Src activation with endosome-mediated delivery to the membrane. Dev. Cell 7 (2004) 855-869
20. Sauter W., Rosenberger A., Beckmann L., Kropp S., Mittelstrass K., Timofeeva M., Wölke G., Steinwachs A., Scheiner D., Meese E., Sybrecht G., Kronenberg F., Dienemann H., Chang-Claude J., Illig T., Wichmann H.E., Bickeböller H., Risch A., and LUCY-Consortium. Matrix metalloproteinase 1 (MMP1) is associated with early-onset lung cancer. Cancer Epidemiol. Biomarkers Prev. 17 (2008) 1127-1135
21. Schütz A., Schneidenbach D., Aust G., Tannapfel A., Steinert M., and Wittekind C. Differential expression and activity status of MMP-1, MMP-2 and MMP-9 in tumor and stromal cells of squamous cell carcinomas of the lung,. Tumour. Biol. 23 (2002) 179-184
22. Singh P.K., Behrens M.E., Eggers J.P., Cerny R.L., Bailey J.M., Shanmugam K., Gendler S.J., Bennett E.P., and Hollingsworth M.A. Phosphorylation of MUC1 by Met modulates interaction with p53 and MMP1 expression. J. Biol. Chem. 283 (2008) 26985-26995
23. Skuli N., Monferran S., Delmas C., Lajoie-Mazenc I., Favre G., Toulas C., and Cohen-Jonathan-Moyal E. Activation of RhoB by hypoxia controls hypoxia-inducible factor-1alpha stabilization through glycogen synthase kinase-3 in U87 glioblastoma cells. Cancer Res. 66 (2006) 482-489
24. Sternlicht M.D., and Werb Z. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol. 17 (2001) 463-516
25. Ullmann U., Gilles C., De Rycke M., Van de Velde H., Sermon K., and Liebaers I. GSK-3-specific inhibitor-supplemented hESC medium prevents the epithelial-mesenchymal transition process and the up-regulation of matrix metalloproteinases in hESCs cultured in feeder-free conditions. Mol. Hum. Reprod. 14 (2008) 169-179
26. Wheeler A.P., and Ridley A.J. Why three Rho proteins? RhoA, RhoB, RhoC, and cell motility. Exp. Cell Res. 301 (2004) 43-49
27. Wheeler A.P., and Ridley A.J. RhoB affects macrophage adhesion, integrin expression and migration. Exp. Cell Res. 313 (2007) 3505-3516
28. Wherlock M., Gampel A., Futter C., and Mellor H. Farnesyltransferase inhibitors disrupt EGF receptor traffic through modulation of the RhoB GTPase. J. Cell Sci. 117 Part 15 (2004) 3221-3231